C9301 Obecabtagene car pos t

Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

• Medicare coverage: Special coverage instructions apply
• Status: terminated 20250630